| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2016-07-25 |
复牌提示：
2016-07-25 11:25:18 停牌，复牌日期 2016-07-25 12:05:00
|
| 2016-05-10 |
详情>>
业绩披露：
2016年一季报每股收益-0.66美元,归母净利润-1626.6万美元,同比去年增长-116.27%
|
| 2016-03-29 |
详情>>
股本变动：
变动后总股本2618.43万股
|
| 2016-03-29 |
详情>>
业绩披露：
2015年年报每股收益-2.29美元,归母净利润-5218.8万美元,同比去年增长-24.72%
|
| 2016-02-27 |
详情>>
内部人交易：
Ticktin Robert等共交易8笔
|
| 2015-11-16 |
详情>>
业绩披露：
2015年三季报(累计)每股收益-1.66美元,归母净利润-3679.4万美元,同比去年增长-17.01%
|
| 2015-08-12 |
详情>>
业绩披露：
2015年中报每股收益-1.07美元,归母净利润-2280.7万美元,同比去年增长-4979.51%
|
| 2015-05-13 |
详情>>
业绩披露：
2015年一季报每股收益-0.39美元,归母净利润-752.1万美元,同比去年增长-98.44%
|
| 2015-04-24 |
股东大会：
将于2015-06-04召开股东大会
会议内容 ▼▲
- 1.To elect Geoffrey Duyk, M.D., Ph.D., Daotian Fu, Ph.D. and Scott Rocklage, Ph.D. as Class I directors to serve a term of three years until our 2018 annual meeting of stockholders (Proposal 1);
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015 (Proposal 2);
3.To approve the EPIRUS Biopharmaceuticals, Inc. 2015 Equity Incentive Plan (Proposal 3);
4.To approve the EPIRUS Biopharmaceuticals, Inc. 2015 Employee Stock Purchase Plan (Proposal 4);
5.To approve an amendment to our sixth amended and restated certificate of incorporation, as amended, to decrease the number of authorized shares of common stock from 300,000,000 to 70,000,000 (Proposal 5);
6.To transact such other business as may properly come before the annual meeting or any adjournments or postponements thereof.
|
| 2015-03-31 |
详情>>
业绩披露：
2014年年报每股收益-6.81美元,归母净利润-4184.4万美元,同比去年增长-8.36%
|
| 2014-11-10 |
详情>>
业绩披露：
2014年三季报(累计)每股收益-8.15美元,归母净利润-3144.5万美元,同比去年增长-141.48%
|
| 2014-08-11 |
详情>>
业绩披露：
2014年中报每股收益-0.17美元,归母净利润-44.9万美元,同比去年增长97.59%
|
| 2014-05-09 |
详情>>
业绩披露：
2014年一季报每股收益-0.15美元,归母净利润-379万美元,同比去年增长52.90%
|
| 2014-03-14 |
详情>>
业绩披露：
2013年年报每股收益-1.68美元,归母净利润-3861.7万美元,同比去年增长12.88%
|
| 2013-04-29 |
股东大会：
将于2013-06-06召开股东大会
会议内容 ▼▲
- 1. To elect Mark H. N. Corrigan, M.D. and Sally W. Crawford as Class II members of the Board of Directors, to serve until the Company’s 2016 Annual Meeting of Stockholders and until their successors are duly elected and qualified;
2. To authorize an amendment to Zalicus’s sixth amended and restated certificate of incorporation to effect a reverse stock split of Zalicus’s issued and outstanding shares of common stock that may be implemented by the Company’s Board of Directors at any time prior to the 2014 annual meeting of stockholders, at its discretion, pursuant to which any whole number of outstanding shares between and including 5 and 10 would be combined and reclassified into one share of Zalicus common stock (such exact amount to be determined by the Zalicus board of directors);
3. To authorize an amendment to our Sixth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000 and authorize our Board of Directors to implement the increase in the number of authorized shares at any time prior to the 2014 annual meeting of stockholders by filing an amendment to our Sixth Amended and Restated Certificate of Incorporation if Proposal No. 2 (Reverse Stock Split) is not approved by the stockholders or our Board of Directors does not implement the reverse stock split described in Proposal No. 2;
4. To ratify the selection of Ernst & Young LLP as the Company’s independent auditors for the fiscal year ending December 31, 2013.
5. To transact any other business that may properly come before the meeting or any adjournment thereof.
|